Team:Hong Kong HKUST/results

From 2013.igem.org

(Difference between revisions)
 
(17 intermediate revisions not shown)
Line 120: Line 120:
}
}
#slide{width:96%;height:auto;background-color:#F4DFC0;margin-top:80px;border:2px solid;
#slide{width:96%;height:auto;background-color:#F4DFC0;margin-top:80px;border:2px solid;
-
border-radius:15px;padding-right:10px;margin-left:15px;}
+
border-radius:15px;padding-right:10px;margin-left:15px;font-family:"Trebuchet MS",Helvetica,sans-serif;float:left;}
 +
#slide1{width:96%;height:auto;background-color:#F4DFC0;margin-top:20px;border:2px solid;
 +
border-radius:15px;padding-right:10px;margin-left:15px;font-family:"Trebuchet MS",Helvetica,sans-serif;float:left;}
.center
.center
{
{
Line 128: Line 130:
}
}
#interview,#presentation,#article, #interview1, #presentation1,#article1
#interview,#presentation,#article, #interview1, #presentation1,#article1
-
{margin-top:20px;width:30%;margin-right:20px;float:left;height:250px; border:2px solid;
+
{margin-top:20px;width:23%;margin-right:10px;float:left;height:230px; border:2px solid;
border-radius:15px;font-family:"Trebuchet MS", Helvetica, sans-serif;}
border-radius:15px;font-family:"Trebuchet MS", Helvetica, sans-serif;}
#interview
#interview
-
{margin-left:25px;background:#e32e51;}
+
{margin-left:0px;background:#e32e51;}
#interview1
#interview1
-
{margin-left:25px;background:#35bb91;}
+
{margin-left:17px;background:#B0B0B0;}
-
#presentation,#article1
+
#presentation{background:#B0B0B0;}
 +
#article1
{background:#35bb91;}
{background:#35bb91;}
#article,#presentation1
#article,#presentation1
{background:#e32e51;}
{background:#e32e51;}
-
#art-desc,#pre-desc,#int-desc{width:50%;float:right;margin-right:8px;}
+
#art-desc,#pre-desc,#int-desc{width:50%;float:right;margin-right:7px;}
-
#art-img,#pre-img,#int-img{width:45%;float:left;margin-left:5px;}
+
#art-img,#pre-img,#int-img{width:45%;float:left;margin-left:4px;}
-
#art-desc-text,#pre-desc-text,#int-desc-text{text-align:justify;float:right;}
+
#art-desc-text,#pre-desc-text,#int-desc-text{float:right;}
h3,h1,#yo{margin-left:10px;font-family:"Trebuchet MS", Helvetica, sans-serif;}
h3,h1,#yo{margin-left:10px;font-family:"Trebuchet MS", Helvetica, sans-serif;}
-
h3.title{font-size:35px;}
+
h3.title{font-size:38px;}
 +
 
 +
#iGEM_Logo{
 +
width:100px;
 +
height:80px;
 +
position:absolute;
 +
right:10px;
 +
top:60px;
 +
z-index:+15;
 +
}
 +
#hkust_Logo{
 +
width:60px;
 +
height:80px;
 +
position:absolute;
 +
right:110px;
 +
top:60px;
 +
z-index:+15;
 +
}
</style>
</style>
</head>
</head>
<body>
<body>
 +
 
 +
          <a href="https://2013.igem.org/Main_Page"><img id="iGEM_Logo" src="https://static.igem.org/mediawiki/2013/4/46/Igem_qgem_logo.png"></a>
 +
         
 +
 +
<a href="http://www.ust.hk/eng/index.htm"><img id="hkust_Logo" src="https://static.igem.org/mediawiki/2013/5/55/Hkust_logo.gif"></a>
 +
<a href=https://2013.igem.org/Team:Hong_Kong_HKUST><center><div id="kepala"><img src="https://static.igem.org/mediawiki/igem.org/c/c7/BANNER1_%281%29.png" style="height:121px;width:100%;"></div></center></a>
<a href=https://2013.igem.org/Team:Hong_Kong_HKUST><center><div id="kepala"><img src="https://static.igem.org/mediawiki/igem.org/c/c7/BANNER1_%281%29.png" style="height:121px;width:100%;"></div></center></a>
Line 207: Line 233:
</div>
</div>
<br><br><br>
<br><br><br>
-
<div id="slide"><center><br><h3 class="title">Result</h3></center><br>
+
<div id="slide"><center><br><h3 class="title">Result</h3></center><br></div>
 +
<div id="interview1"><h3>Experiment 1: Glyoxylate Shunt</h3><div id="art-img"><br><img src="https://static.igem.org/mediawiki/2013/c/c0/Expt3.png" style="padding-left:5px;width:90%;padding-top:5px;"><center><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/experiment/exp4"><img src="http://w1ggroup.com/devere/img/more_off.png" style="width:80%;height:40px;padding-top:10px;"></a></center></div><div id="art-desc"><p id="art-desc-text"><br>Introduce glyoxylate enzymes responsible for the shunt</p></div></div>
 +
 
 +
<div id="interview"><h3>Experiment 2: Protein Trafficking</h3><div id="pre-img"><br><img src="https://static.igem.org/mediawiki/2013/4/45/Expt2.png" style="padding-left:5px;width:105%;padding-top:8px;"><center><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/experiment/exp3"><br><img src="http://w1ggroup.com/devere/img/more_off.png" style="width:75%;height:40px;padding-top:2px;"></a></center></div><div id="pre-desc"><p id="pre-desc-text"><br>Target ACE proteins into mitochondria</p></div></div>
 +
 
 +
<div id="presentation"><h3>Experiment 3: Fatty Acid Sensing Mechanism</h3><div id="pre-img"><br><img src="https://static.igem.org/mediawiki/2013/4/4f/Expt1.png" style="padding-left:5px;padding-top:5px;width:90%;"><center><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/experiment/exp2"><img src="http://w1ggroup.com/devere/img/more_off.png" style="width:80%;height:40px;padding-top:10px;"></a></center></div><div id="pre-desc"><p id="pre-desc-text"><br>Introduce inducible system that allows tunable fatty acid uptake by sensing fatty acid concentration</p></div></div>
 +
 
 +
<div id="article"><h3>Experiment 4: Cell Viability & Fatty Acid Quantification</h3><div id="pre-img"><br><img src="https://static.igem.org/mediawiki/2013/f/fa/Expt0.png" style="padding-left:2px;padding-top:5px;width:90%;"><center><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/experiment/exp1"><img src="http://w1ggroup.com/devere/img/more_off.png" style="width:80%;height:40px;padding-top:10px;"></a></center></div><div id="pre-desc"><br><p id="pre-desc-text">Measuring cell viability at different fatty acid concentration & measure fatty acid uptake rate</p></div></div>
 +
<div id="slide1">
<p id="yo">Our project was first proposed in mid-March and after a series of improvement and elaboration, we started our wet lab work from mid-June to late-September. After 3 months of memorable diligent work, we are proud to claim that we have achieved the results below:
<p id="yo">Our project was first proposed in mid-March and after a series of improvement and elaboration, we started our wet lab work from mid-June to late-September. After 3 months of memorable diligent work, we are proud to claim that we have achieved the results below:
<ul>
<ul>
-
   <li>Successfully constructed the two parts</a> for mitochondria leader sequence, MLS with RFC 10 and RFC 25, (<a href="http://parts.igem.org/Part:BBa_K1119000">BBa_K1119000</a>, <a href="http://parts.igem.org/Part:BBa_K1119001">BBa_K1119001</a>).</li>
+
   <li>Successfully constructed two parts</a> carrying mitochondrial leader sequence (MLS) compatible with RFC 10 and RFC 25 assembly standards respectively, (<a href="http://parts.igem.org/Part:BBa_K1119000">BBa_K1119000</a>, <a href="http://parts.igem.org/Part:BBa_K1119001">BBa_K1119001</a>).</li>
-
   <li>Successfully constructed the </a>part of  aceA and aceB for in glyoxylate shunt (<a href="http://parts.igem.org/Part:BBa_K1119002">BBa_K1119002</a>, <a href="http://parts.igem.org/Part:BBa_K1119003">BBa_K1119003</a>). </li>
+
   <li>Successfully constructed </a>parts containing the <i>aceA</i> and <i>aceB</i> elements of the glyoxylate shunt (<a href="http://parts.igem.org/Part:BBa_K1119002">BBa_K1119002</a>, <a href="http://parts.igem.org/Part:BBa_K1119003">BBa_K1119003</a>). </li>
-
   <li>Successfully constructed the part of a constitutive regulatory promoter, Human Elongation Factor 1-alpha promoter (<a href="http://parts.igem.org/Part:BBa_K1119004">BBa_K1119004</a>).</li>
+
   <li>Successfully constructed a part containing the constitutive CMV promoter (<a href="http://parts.igem.org/Part:BBa_K1119006">BBa_K1119006</a>).</li>
-
   <li>Successfully construct the part for a constitutive CMV promoter (<a href="http://parts.igem.org/Part:BBa_K1119006">BBa_K1119006</a>).</li>
+
   <li>Successfully characterized the constitutive CMV promoter in HEK293FT cells (<a href="http://parts.igem.org/Part:BBa_K1119008">BBa_K1119008</a>).</li>
-
  <li>Successfully characterized the regulatory promoter <em>pCMV</em> in HEK293FT cells (<a href="http://parts.igem.org/Part:BBa_K1119008">BBa_K1119008</a>).</li>
+
<li>Successfully constructed a part containing the constitutive regulatory promoter of Human Elongation Factor 1-alpha (<a href="http://parts.igem.org/Part:BBa_K1119010">BBa_K1119010</a>).</li>
-
   <li>Successfully characterized the mitochondria leader sequence MLS in HEK293FT cells (<a href="http://parts.igem.org/Part:BBa_K1119009">BBa_K1119009</a>).</li>
+
<li>Successfully characterized the constitutive EF-1alpha promoter in HEK293FT cells (<a href="http://parts.igem.org/Part:BBa_K1119011">BBa_K1119011</a>).</li>
-
   <li>Successfully tested the HepG2 cell viability in different sodium palmitate concentrations. </li>
+
   <li>Successfully characterized the mitochondrial leader sequence (MLS) in HEK293FT cells (<a href="http://parts.igem.org/Part:BBa_K1119009">BBa_K1119009</a>).</li>
 +
   <li>Successfully tested HepG2 cell viability in different sodium palmitate concentrations. </li>
</ul></p>
</ul></p>
-
<br><br>
+
<br>
</div>
</div>
-
 
+
</body>
</html>
</html>

Latest revision as of 12:53, 28 October 2013





Result


Experiment 1: Glyoxylate Shunt



Introduce glyoxylate enzymes responsible for the shunt

Experiment 2: Protein Trafficking




Target ACE proteins into mitochondria

Experiment 3: Fatty Acid Sensing Mechanism



Introduce inducible system that allows tunable fatty acid uptake by sensing fatty acid concentration

Experiment 4: Cell Viability & Fatty Acid Quantification



Measuring cell viability at different fatty acid concentration & measure fatty acid uptake rate

Our project was first proposed in mid-March and after a series of improvement and elaboration, we started our wet lab work from mid-June to late-September. After 3 months of memorable diligent work, we are proud to claim that we have achieved the results below:

  • Successfully constructed two parts carrying mitochondrial leader sequence (MLS) compatible with RFC 10 and RFC 25 assembly standards respectively, (BBa_K1119000, BBa_K1119001).
  • Successfully constructed parts containing the aceA and aceB elements of the glyoxylate shunt (BBa_K1119002, BBa_K1119003).
  • Successfully constructed a part containing the constitutive CMV promoter (BBa_K1119006).
  • Successfully characterized the constitutive CMV promoter in HEK293FT cells (BBa_K1119008).
  • Successfully constructed a part containing the constitutive regulatory promoter of Human Elongation Factor 1-alpha (BBa_K1119010).
  • Successfully characterized the constitutive EF-1alpha promoter in HEK293FT cells (BBa_K1119011).
  • Successfully characterized the mitochondrial leader sequence (MLS) in HEK293FT cells (BBa_K1119009).
  • Successfully tested HepG2 cell viability in different sodium palmitate concentrations.


Retrieved from "http://2013.igem.org/Team:Hong_Kong_HKUST/results"